Overview
Our study is conducted to recruit cervical cancer screening patients to evaluate the application value of using high-throughput sequencing technology to detect HPV in menstrual blood for cervical cancer screening.
Description
Our study aims to recruit 10,000 cervical cancer screening patients from the outpatient department of Zhongnan Hospital of Wuhan University from September 1, 2023 to March 31, 2028. The procedures were conducted as below: (1) Conduct cervical cancer screening (TCT+cobas-HPV) for all the participants. (2) Collect sanitary napkins from participants during their first menstrual period after cervical HPV testing. (3) Detect HPV using high-throughput sequencing technology in the menstrual blood (MB) from sanitary napkins. (4) Colposcopy referral (biopsy if necessary) for patients with abnormal screening results. (5) Compare the concordance between MB-HPV and cobas-HPV.
Eligibility
Inclusion Criteria:
- plan to undergo cervical screening
- with regular menstruation
- agree to participate in this study and have signed an informed consent form
Exclusion Criteria:
- with amenorrhea or menopause
- suffering from genital tract infection
- refuse to participate in this study